Clinical Scorecard: Impact of Early IL-1 Blockade on Long-Term Outcomes in Pediatric Still's Disease: Insights from a Real-World Cohort Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Systemic inflammation driven by dysregulated innate immunity and excessive activation of monocytes and macrophages, particularly involving IL-1 and IL-6.
Target Population
Care Setting
Key Highlights
11.1% achieved clinical inactive disease (CID) at 1 month.
66.7% achieved clinical inactive disease (CID) at 3 months.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical criteria including quotidian fever, evanescent rash, and laboratory findings such as leukocytosis, thrombocytosis, and elevated acute-phase reactants.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Biologic therapy duration prior to discontinuation was median 14.5 months. Patient demographics included 50% female with a median age at symptom onset of 6.5 years.
Clinical Best Practices
Implement early IL-1 blockade as part of treat-to-target strategies.
Evaluate for MAS and manage with concomitant therapies as needed.
Consider patient and parent perceptions in treatment assessments, including the observed 'perception lag' during early treatment.
